Bhatt’s study, "Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts,” was recently published in The New England Journal of Medicine. Bhatt and colleagues conducted a multicenter ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. “Type 2 myocardial infarction occurs due to a mismatch ...

A biologic injection that reduces chronic obstructive pulmonary disease (COPD) flare-ups by around a third has been approved for use on the NHS in England and Wales. The National Institute for Health ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. The phase 3 BOREAS trial included adults with ...

Inflammation that develops in chronic obstructive pulmonary disorder stems from different causes. A new regulatory decision in Europe makes Sanofi and Regeneron Pharmaceuticals drug Dupixent the first ...

Chronic obstructive pulmonary disease patients with type 2 inflammation may soon gain access to a new drug — dupilumab — that showed rapid and sustained improvements in patients in a pivotal Phase 3 ...

Chronic obstructive pulmonary disease patients with type 2 inflammation saw rapid and sustained improvements in their disease after treatment with the monoclonal antibody dupilumab, according to a ...

Priority Review granted based on positive results from two Phase 3 trials If approved, Dupixent would be the only biologic therapy for COPD and the first new treatment approach for the disease in more ...